<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="136051">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01740180</url>
  </required_header>
  <id_info>
    <org_study_id>LOCAL/2012/GT</org_study_id>
    <secondary_id>Taieb Cohorte CLIPPERS</secondary_id>
    <nct_id>NCT01740180</nct_id>
  </id_info>
  <brief_title>Cortico-saving Treatments Proposed for CLIPPERS: a First Cohort</brief_title>
  <official_title>Cortico-saving Treatments Proposed for CLIPPERS (Chronic Lymphocytic Inflammation With Pontine Perivascular Responsive to Steroids): a First Cohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <authority>France: Comité consultatif sur le traitement de l'information en matière de recherche dans le domaine de la santé</authority>
    <authority>France: The Commission nationale de l’informatique et des libertés</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to collect information about how CLIPPERS patients
      are currently being treated in France.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observational study.  Data will be prospectively collected, starting with a
      detailed baseline description of disease and treatment status, followed by updates
      everything six months for the next three years.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Presence/absence of cortico-sparing treatments</measure>
    <time_frame>baseline to 3 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence/absence of allergies</measure>
    <time_frame>Baseline (day 0)</time_frame>
    <safety_issue>No</safety_issue>
    <description>+ description</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete description of all treatments being taken</measure>
    <time_frame>Baseline (day 0)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLIPPERS relapse severity</measure>
    <time_frame>Baseline (day 0)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The rhythm and severity of relapses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free interval rhythm</measure>
    <time_frame>Baseline (day 0)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight (kg)</measure>
    <time_frame>Baseline (day 0)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence/absence of vascular risk factors</measure>
    <time_frame>Baseline (Day 0)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of relapses in the past 6 months while taking &gt;= 20 mg/ day corticoids</measure>
    <time_frame>Baseline (day 0)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence/absence of allergies</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>+ description</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence/absence of allergies</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>+ description</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence/absence of allergies</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>+ description</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence/absence of allergies</measure>
    <time_frame>21 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>+ description</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence/absence of allergies</measure>
    <time_frame>24  months</time_frame>
    <safety_issue>No</safety_issue>
    <description>+ description</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence/absence of allergies</measure>
    <time_frame>30  months</time_frame>
    <safety_issue>No</safety_issue>
    <description>+ description</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence/absence of allergies</measure>
    <time_frame>36  months</time_frame>
    <safety_issue>No</safety_issue>
    <description>+ description</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete description of all treatments being taken</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete description of all treatments being taken</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete description of all treatments being taken</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete description of all treatments being taken</measure>
    <time_frame>21 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete description of all treatments being taken</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete description of all treatments being taken</measure>
    <time_frame>30 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete description of all treatments being taken</measure>
    <time_frame>36 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLIPPERS relapse severity</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The rhythm and severity of relapses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLIPPERS relapse severity</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The rhythm and severity of relapses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLIPPERS relapse severity</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The rhythm and severity of relapses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLIPPERS relapse severity</measure>
    <time_frame>21 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The rhythm and severity of relapses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLIPPERS relapse severity</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The rhythm and severity of relapses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLIPPERS relapse severity</measure>
    <time_frame>30 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The rhythm and severity of relapses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLIPPERS relapse severity</measure>
    <time_frame>36 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The rhythm and severity of relapses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free interval rhythm</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free interval rhythm</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free interval rhythm</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free interval rhythm</measure>
    <time_frame>21 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free interval rhythm</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free interval rhythm</measure>
    <time_frame>30 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free interval rhythm</measure>
    <time_frame>36 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight (kg)</measure>
    <time_frame>6  months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight (kg)</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight (kg)</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight (kg)</measure>
    <time_frame>21 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight (kg)</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight (kg)</measure>
    <time_frame>30 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight (kg)</measure>
    <time_frame>36 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence/absence of vascular risk factors</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence/absence of vascular risk factors</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence/absence of vascular risk factors</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence/absence of vascular risk factors</measure>
    <time_frame>21 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence/absence of vascular risk factors</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence/absence of vascular risk factors</measure>
    <time_frame>30 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence/absence of vascular risk factors</measure>
    <time_frame>36 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of relapses in the past 6 months while taking &gt;= 20 mg/ day corticoids</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of relapses in the past 6 months while taking &gt;= 20 mg/ day corticoids</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of relapses in the past 6 months while taking &gt;= 20 mg/ day corticoids</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of relapses in the past 6 months while taking &gt;= 20 mg/ day corticoids</measure>
    <time_frame>21 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of relapses in the past 6 months while taking &gt;= 20 mg/ day corticoids</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of relapses in the past 6 months while taking &gt;= 20 mg/ day corticoids</measure>
    <time_frame>30 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of relapses in the past 6 months while taking &gt;= 20 mg/ day corticoids</measure>
    <time_frame>36 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Family history of auto-immune disease</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Height (cm)</measure>
    <time_frame>Baseline (day 0)</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">15</enrollment>
  <condition>CLIPPERS</condition>
  <arm_group>
    <arm_group_label>CLIPPERS patients</arm_group_label>
    <description>The population concerned by this study consists of patients diagnosed according to CLIPPERS criteria (see inclusion and exclusion criteria).
Intervention: Data entry</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Data entry</intervention_name>
    <description>This cohort describes the basic information about the patients (age, sex, weight, height, background) as well as acts required, treatment and results of imaging studies.
These data are extracted from patient records by each participating center and collected in an e-CRF.</description>
    <arm_group_label>CLIPPERS patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The population concerned by this study consists of patients diagnosed according to
        CLIPPERS criteria (see inclusion and exclusion criteria).

        Patients will be recruited from referral centers throughout France. We also intend to
        communicate with all multiple sclerosis networks (French League against Multiple
        Sclerosis) to facilitate the detection of new cases.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient correctly informed about the study

          -  Symptoms and/or clinical signs indicating that the brain stem is affected

          -  MRI shows punctate gadolinium highlights and/or curvilinear bridge and/or middle
             cerebellar peduncles

          -  Clinical and radiological cortico sensitivity

          -  If a cerebral biopsy has been performed, presence of a lymphocytic, histiocytic or
             lympho-hysticytic infiltrate

        Exclusion Criteria:

          -  symptoms and/or clinical signs indicating impairment other than the central nervous
             system

          -  Cortical impairment present on MRI, microbleeds, stenosis on magnetic resonance
             angiography, or pacchymeningitis

          -  Presence of other diseases that could explain such clinical and radiological signs
             (see inclusion criteria)

          -  If a cerebral biopsy has been performed, presence of signs of malignancy (eg, clonal
             proliferation, cellular atypia), vasculitis, granuloma, or demyelination
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillaume Taieb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nîmes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guillaume Taieb, MD</last_name>
    <phone>+33.(0)4.66.68.21.99</phone>
    <email>guillaume.taieb@chu-nimes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carey Suehs, PhD</last_name>
    <phone>+33.(0)4.66.68.67.88</phone>
    <email>carey.suehs@chu-nimes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Bordeaux - Groupe Hospitalier Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Sandrine Eimer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Dax - Côte d'Argent</name>
      <address>
        <city>Dax</city>
        <zip>40100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Patrice Desbordes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges - Hôpital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Laurent Magy, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHM - Hôpital La Timone Adultes</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Bertrand Audoin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elsa Kaphan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean Pelletier, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominique Figarella Branger, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier - Hôpital Saint-Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Thierry Vincent, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nîmes - Hôpital Universitaire Carémeau</name>
      <address>
        <city>Nîmes Cedex 9</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen - Hôpital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Romain Lefaucheur, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Maltete, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Strasbourg - Hôpital Civil</name>
      <address>
        <city>Strasbourg Cedex</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Stephane Kremer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jérome de Sèze, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine Tranchant, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Toulouse - Hôpital Purpan</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>David Brassat, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michel Clanet, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Toulouse - Hôpital de Rangueil</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Emmanuelle Uro-Coste, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Tours - Hôpital Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Nadège Limousin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 3, 2014</lastchanged_date>
  <firstreceived_date>November 30, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
